Phase II study of vatalanib and octreotide in patients with progressive low-grade neuroendocrine tumors
Latest Information Update: 03 Nov 2021
Price :
$35 *
At a glance
- Drugs Octreotide (Primary) ; Vatalanib (Primary)
- Indications Neuroendocrine carcinoma
- Focus Therapeutic Use
- 31 Oct 2006 Status change
- 15 Dec 2005 New trial record.